Clinical trial · Observational
Timing of ctDNA Testing in Advanced Breast Cancer
Timing of ctDNA Testing in Advanced Breast Cancer: Impact on Prognosis and Treatment Strategies - A Prospective Observational Study (TIMING)
NCT07681323CI-TRIAL-00119009TIMINGrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- From diagnosis until death or study completion, up to 3 years
Secondary outcomes (4)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- From treatment initiation to progression or death, assessed every 8-12 weeks
- measure
- Objective Response Rate (ORR)
- timeFrame
- From treatment initiation to end of treatment, assessed every 8-12 weeks
- measure
- Correlation of ctDNA level, gene mutations , clonality with treatment response and OS
- timeFrame
- From diagnosis to death, up to 3 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed advanced breast cancer * Age ≥18 years * Expected survival \>3 months * Willing to undergo ctDNA testing and sign informed consent form Exclusion Criteria: * The subject has not signed the informed consent form. * Pregnant or breastfeeding women. * Other situations deemed by the investigator as unsuitable for inclusion in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.